Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 12/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.57 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.57 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.57 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 9/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.57 |
| ▸ | GABRP | O00591 | 6/20 | 0.57 |
| ▸ | GABRD | O14764 | 6/20 | 0.57 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.57 |
| ▸ | GABRE | P78334 | 6/20 | 0.57 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.57 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.57 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | PDE5A | O76074 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014349 | 0.85 | GABRP (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1427311 | 0.79 | GABRA1 (0.71) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL674216 | 0.73 | ERBB2 (0.48) | ALDH1A1KDM4EHPGDHSD17B10AURKA | |
| SCHEMBL15806833 | 0.73 | ALDH1A1 (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Beta-Ccm SCHEMBL1066725 | 0.73 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Beta-Ccm SCHEMBL30480071 | 0.73 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL6518381 | 0.72 | AURKA (0.58) | ALDH1A1KDM4EHPGDHSD17B10AURKA | |
| SCHEMBL6524053 | 0.72 | AURKA (0.58) | ALDH1A1KDM4EHPGDHSD17B10AURKA | |
| SCHEMBL10405046 | 0.72 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Beta-Ccm SCHEMBL28185000 | 0.72 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2513110-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328195-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | GABRA1 2256/4885GABRG2 3123/4885GABRB3 1614/4885 |
| US-20110183938-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | GABRA1 2256/4885GABRG2 3123/4885GABRB3 1614/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | GABRA1 2256/4885GABRG2 3123/4885GABRB3 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.